Bristol-Myers, Ono Pharmaceutical sales and marketing update

The U.K.’s NICE issued final draft guidance recommending the use of Opdivo nivolumab from Bristol-Myers Squibb to treat advanced renal cell carcinoma (RCC) after prior therapy. The recommendation is contingent upon BMS providing the human IgG4 mAb against PD-1 at an undisclosed discount under a patient access scheme. The agency noted that Opdivo causes fewer side effects than Inlyta axitinib and everolimus and patients taking Opdivo lived an average of five months longer than patients taking everolimus...